{"podcast":{"title":"Blood Cancer Talks","slug":"blood-cancer-talks-5570002","podcast_index_feed_id":5570002,"rss_url":"https://feeds.transistor.fm/bloodcancertalks","website_url":null,"image_url":"https://img.transistorcdn.com/W_5G4oA5kAcf9vixuJQw-sMFE98Hvnnp4pex_BzuYvE/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.jpg","author":"Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff","episode_count":75,"summary":"This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk","last_synced_at":"2026-09-03T22:19:58.611204+00:00","page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002"},"episode":{"title":"Episode 61. Menin Inhibitors in AML with Dr. Eytan Stein","slug":"episode-61-menin-inhibitors-in-aml-with-dr-eytan-stein","published_at":"2025-06-24T11:31:16+00:00","page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-61-menin-inhibitors-in-aml-with-dr-eytan-stein","show_page_url":"https://stenobird.com/podcast/blood-cancer-talks-5570002","url":"https://share.transistor.fm/s/f91d6c00","audio_url":"https://media.transistor.fm/f91d6c00/a39bdd8d.mp3","summary":"In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022 Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6 DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79 AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826 Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutated KOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstract SAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-of KOMET-007: https://library.ehaweb.org/eha/2025/eha2025-congress/4159213/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5843%2Afeatured%3D19595 MEN1 mutations: https://www.nature.com/articles/s41586-023-05755-9","meta_description":"In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies w…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3384,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-61-menin-inhibitors-in-aml-with-dr-eytan-stein/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-61-menin-inhibitors-in-aml-with-dr-eytan-stein.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}